Reuters logo
BRIEF-Immunogen and Sanofi amend license agreements
May 30, 2017 / 12:51 PM / 4 months ago

BRIEF-Immunogen and Sanofi amend license agreements

May 30 (Reuters) - Immunogen Inc

* Immunogen and Sanofi amend license agreements

* Immunogen - co, affiliate of Sanofi have amended their license agreements covering all compounds in development by sanofi using Immunogen’s technology

* Immunogen Inc - as consideration for these amendments, Immunogen will receive a $30 million payment

* Immunogen - as consideration for amendments immunogen agreed to forego limited co-promotion option in U.S. With respect to compounds covered by 2003 agreement

* Immunogen - as consideration for amendments immunogen has also agreed to forego future milestones or royalties under both license agreements

* Immunogen Inc - also amended to grant Sanofi fully-paid, exclusive license to develop, manufacture, commercialize experimental compound SAR428926 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below